Acquired Hemophilia A Market

Market Overview:

The 7 major acquired hemophilia A markets reached a value of US$ 9.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.34% during 2024-2034.

The acquired hemophilia A market has been comprehensively analyzed in IMARC's new report titled "Acquired Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acquired hemophilia A is a rare and potentially life-threatening bleeding disorder characterized by the development of antibodies, called inhibitors, that target and neutralize clotting factor VIII, a vital protein responsible for normal blood coagulation. This disease typically occurs later in life, often affecting individuals with no prior history of bleeding disorders. The symptoms of the illness are marked by spontaneous and excessive bleeding that can manifest as prolonged or uncontrollable bleeding from minor injuries, mucous membranes, and soft tissues. Bruising, joint pain, and gastrointestinal or urinary tract bleeding may also occur. These indications can be severe and require immediate medical attention. Diagnosing acquired hemophilia A involves a comprehensive assessment of bleeding symptoms, medical history, and laboratory tests to detect the presence of clotting factor inhibitors. Coagulation studies, such as the activated partial thromboplastin time and clotting factor assays, are also utilized to confirm the diagnosis by revealing prolonged clotting times and reduced factor VIII activity.

The increasing prevalence of bleeding disorders that can cause the sudden development of autoantibodies against clotting factor VIII is primarily driving the acquired hemophilia A market. In addition to this, the inflating utilization of efficacious treatments, such as bypassing agents and immune tolerance induction, is creating a positive outlook for the market. These interventions, tailored to neutralize inhibitors and enhance coagulation, play a pivotal role in managing and mitigating the severity of bleeding episodes. Moreover, the widespread integration of personalized treatment approaches customized to individual patient profiles, leveraging advancements in diagnostics and precision medicine, is further bolstering the market growth. Apart from this, the rising usage of physical and rehabilitative strategies on account of their various benefits, like enhancing joint mobility, muscular strength, and overall quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of rituximab, an anti-CD20 monoclonal antibody, since it helps to mitigate the immune response that leads to inhibitor formation, is also augmenting the market growth. Furthermore, the escalating demand for innovative techniques, such as gene editing and targeted therapies, that can rectify the underlying genetic aberrations responsible for the disorder is expected to drive the acquired hemophilia A market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the acquired hemophilia A market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acquired hemophilia A and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acquired hemophilia A market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acquired hemophilia A market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acquired hemophilia A market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acquired hemophilia A marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acquired hemophilia A market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acquired hemophilia A market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acquired hemophilia A market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of acquired hemophilia A across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acquired hemophilia A by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acquired hemophilia A by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with acquired hemophilia A across the seven major markets?
• What is the size of the acquired hemophilia A patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acquired hemophilia A?
• What will be the growth rate of patients across the seven major markets?
   

Acquired Hemophilia A: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acquired hemophilia A drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acquired hemophilia A market?
• What are the key regulatory events related to the acquired hemophilia A market?
• What is the structure of clinical trial landscape by status related to the acquired hemophilia A market?
• What is the structure of clinical trial landscape by phase related to the acquired hemophilia A market?
• What is the structure of clinical trial landscape by route of administration related to the acquired hemophilia A market?